Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 4.0% during the 4th quarter, HoldingsChannel reports. The firm owned 1,989,340 shares of the biotechnology company’s stock after buying an additional 76,196 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Iovance Biotherapeutics were worth $14,721,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in Iovance Biotherapeutics during the 4th quarter worth $515,000. Jennison Associates LLC acquired a new stake in Iovance Biotherapeutics during the 4th quarter worth $493,000. Barclays PLC boosted its stake in Iovance Biotherapeutics by 118.8% during the 3rd quarter. Barclays PLC now owns 604,584 shares of the biotechnology company’s stock worth $5,677,000 after purchasing an additional 328,284 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Iovance Biotherapeutics by 59.0% during the 3rd quarter. Principal Financial Group Inc. now owns 4,033,184 shares of the biotechnology company’s stock worth $37,872,000 after purchasing an additional 1,496,941 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Iovance Biotherapeutics during the 3rd quarter worth $920,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

Analyst Upgrades and Downgrades

IOVA has been the topic of several analyst reports. The Goldman Sachs Group reduced their price target on Iovance Biotherapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. Piper Sandler reduced their price target on Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating on the stock in a report on Friday, February 28th. Truist Financial reduced their price target on Iovance Biotherapeutics from $25.00 to $15.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a report on Friday, February 28th. Finally, Chardan Capital reduced their price target on Iovance Biotherapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Iovance Biotherapeutics has an average rating of “Moderate Buy” and an average target price of $20.25.

Iovance Biotherapeutics Trading Down 0.6 %

Shares of IOVA opened at $3.54 on Friday. The firm has a market cap of $1.16 billion, a P/E ratio of -2.38 and a beta of 0.93. Iovance Biotherapeutics, Inc. has a 12-month low of $3.48 and a 12-month high of $15.90. The company’s 50-day moving average price is $5.18 and its 200 day moving average price is $7.85.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.26). The firm had revenue of $73.69 million for the quarter, compared to analyst estimates of $72.17 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. Equities research analysts forecast that Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current year.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.